GenScript Launches AI Life Sciences Startup Competition
News related to:GenScript Biotech Corporation · 2 min read
PISCATAWAY, N.J. and SANTA CLARA, Calif., Oct. 8, 2026 /CourierPR/ -- GenScript Biotech Corporation, a biotech firm established in 2002 in New Jersey, has expanded its global reach to over 200,000 customers across 100+ countries and regions, including the world's top 20 pharmaceutical companies. The company, which boasts a team of 6,100+ employees, is set to host the inaugural GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition designed to connect emerging artificial intelligence (AI) life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week.
The program, which brings together GenScript’s wet lab validation and data generation capabilities and NVIDIA’s accelerated computing platforms and startup ecosystem, aims to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility. Up to six finalists will be selected for a GenScript-hosted pitch event during JPM Week in January, before a panel of judges. The winning company will receive GenScript wet lab data credits and Brev credits from NVIDIA to support its development efforts.
The GenScript and NVIDIA Life Sciences Startup PitchFest is designed to harness the true potential of AI in life sciences by connecting digital biology startups with investors, technology leaders, and partners focused on turning computational predictions into biological proof. The competition will feature startups developing technologies such as AI-driven antibody and protein design, as well as technologies that accelerate the design-build-test-learn cycle.
To Ray Chen, President of GenScript Life Science Group, the success in this space requires a connected pathway that brings together data, experimental evidence, and investment to help innovators move from computational promise to therapeutic progress. The PitchFest gives digital biology startups integrated support to rapidly test their models, generate evidence, and accelerate breakthrough therapies.
Through the competition, GenScript will contribute sequence-to-data capabilities and experimental validation expertise, while NVIDIA will provide access to NVIDIA Inception, its free program that helps startups build, scale, and connect across the NVIDIA platform and ecosystem. Together, GenScript and NVIDIA will help selected startups move from promising AI-driven concepts toward stronger biological evidence, investor readiness, and potential partnerships.
Finalists will also be invited to GenScript’s Biotech Global Forum, where they can engage with biotechnology executives, strategic partners, and industry leaders focused on the future of AI-enabled discovery. Additional details on judging criteria, speakers, and investor participation will be announced in the coming weeks as the program helps AI-driven life science startups generate evidence, build industry relationships, and accelerate their own commercialization journeys.
The GenScript and NVIDIA Life Sciences Startup PitchFest is a pivotal moment for the biotech industry, as it brings together the power of AI and validation expertise to accelerate the development of innovative therapeutic solutions. As the competition unfolds, the potential for groundbreaking breakthroughs in the field of biotechnology is immense, with the ultimate goal of bringing these technologies from the lab to the clinic.